# A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

> **NCT00723957** · PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 260 (actual)

## Conditions studied

- Advanced/Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Ixabepilone, 32 mg/m^2
- **DRUG:** Paclitaxel, 200 mg/m^2
- **DRUG:** Carboplatin (area under the concentration curve [AUC] 6)

## Key facts

- **NCT ID:** NCT00723957
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-05
- **Final completion:** 2011-08
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723957, "A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00723957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*